الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Ovarian cancer is one of the most common cancers among females worldwide. Its pathogenesis is not well understood till now. FLOT-1 is expressed in a wide range of normal and neoplastic tissues and has emerged as an important regulator cellular adhesion, proliferation, and metastasis. Its role in ovarian serous carcinogenesis is not clear and needs further studies.
Aim: The present study was conducted to study the immunohistochemical expression of FLOT-1 in serous ovarian tumors, in order to evaluate its expression pattern and to examine its association with various clinicopathological features.
Materials and Methods: The present study comprised 72 cases of serous ovarian tumors including; 50 (69.44%) cases of serous ovarian carcinoma, 12 (16.67%) cases of borderline serous ovarian tumors and 10 (13.89%) cases of serous ovarian cyst-adenoma. Immunohistochemistry for FLOT-1 antibody was performed using the avidin biotin-peroxidase complex method.
Results: FLOT-1 was positive in 54% of serous ovarian carcinoma cases, 50% of borderline cases were positive and all serous cystadenoma cases were negative. Statistically significant association was detected between FLOT-1 expression and grade of differentiation of serous ovarian carcinoma cases (p=0.000). Meanwhile, no statistically significant association was found between FLOT-1 expression and age, tumor size, tumor bi-laterality and tumor stage (p=0.179, 0.643, 0.093, 0.187 respectively). In serous borderline cases, there were no statistically significant association between FLOT-1 expression and age, tumor size and tumor bi-laterality (p= 0.558, 0.558, 0.121 respectively).
Conclusion: FLOT-1 expression is significantly associated with poor prognostic factors and thus can be used as a prognostic indicator for serous ovarian carcinoma patients.